Bessemer Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Bessemer Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-76	Closed	–	–	1815
2019 Q3	$0	Buy	+76	New	+$469	﹤0.01%	1854

Other funds holding ADMS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Bessemer Group's ADMS Position: Q4 2019 in Review

Bessemer Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 76 shares.

Bessemer Group first reported a position in ADMS in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

Bessemer Group reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Bessemer Group sold 76 Adamas Pharmaceuticals shares in Q4 2019.
Bessemer Group first reported a position in Adamas Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Bessemer Group's Adamas Pharmaceuticals position peaked at $0 in Q3 2019.
79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Bessemer Group's 13F filing for Q4 2019, filed 4 Feb 2020.